Partnering

SNBL seeks to establish strategic partnership of our nasal drug delivery technology with pharmaceutical companies. After conducting a evaluation program to fulfill client’ s needs, as shown as below, we would license our technology (e.g. by compound, indication, area of application, nation/region, etc.).

Feasibility Study Program

Licensee of Platform Technology

Satsuma Pharmaceuticals, Inc. (USA)

Satsuma Pharmaceuticals, Inc. (Satsuma) was established in the US by SNBL primarily for the purpose of furthering the development of a migraine treatment drug (dihydroergotamine, DHE) applying SNBL licensing platform technology related to the development of a nasal DHE product (STS101).

Satsuma was listed on the NASDAQ in the United States on September 13, 2019.

Satsuma completed Phase III clinical trials for STS101 in 2022 and submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (“FDA”) in March 2023.

On April 16, 2023, SNBL announced that it had entered into a definitive agreement to acquire Satsuma and as a result of the completion of the transaction, Satsuma will become a consolidated subsidiary of SNBL.

With the acquisition of Satsuma, SNBL will acquire exclusive worldwide rights to develop, manufacture and commercialize STS101.